Milestone is on track to initiate a Phase 3 trial evaluating etripamil in AFib-RVR in 2025. The protocol of a Phase 3, potentially registrational study has been finalized and study start-up has ...
This may contribute to the development of heart failure over time. AFib with a rapid ventricular response (elevated heart rates greater than 100 beats per minute at rest) can result in overworking ...
Milestone is also on track to initiate a Phase 3 trial for etripamil in patients with AFib-RVR in 2025. A recent investor event detailed the commercialization strategy for CARDAMYST. We have seen ...
Hosted on MSN1mon
H.C. Wainwright maintains $25 target on Milestone sharesAdditionally, Milestone Pharmaceuticals is planning to initiate a Phase 3 program in the first half of 2025 for atrial fibrillation with rapid ventricular rate (AFib-RVR). Success in this program ...
It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid ...
Milestone Pharmaceuticals Inc. announced that the PDUFA date for its nasal spray CARDAMYST™ (etripamil) for treating Paroxysmal Supraventricular Tachycardia (PSVT) has been set for March 27, 2025.
Milestone is on track to initiate a Phase 3 trial evaluating etripamil in AFib-RVR in 2025. The protocol of a Phase 3, potentially registrational study has been finalized and study start-up has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback